Our Pipeline

Our robust pipeline includes investigational RNAi therapeutics for rare, genetic, cardio-metabolic, infectious and CNS and ocular diseases.

Late Stage

Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, complement mediated diseases, and severe primary hyperoxaluria type 1.

Early Stage

Learn more about our investigational therapies across multiple disease areas.

Alnylam Medical Publication Support

Alnylam may consider providing publication support in response to an unsolicited request from a healthcare professional. Learn more about how Alnylam may be able to provide support for these requests.

Alnylam Grant Information

Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Additionally, we are committed to supporting educational programs and initiatives spearheaded by organizations focused on patient advocacy, community education and support, and other scientific efforts related to our therapeutic areas of interest. To learn more about grants, sponsorships, or how to submit a grant request, visit our grants page.

Access to Investigational Medicines

Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families, and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician with pre-approval access to a specific Alnylam investigational medicine, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met.

To read our statement on access to investigational medicines, click here.

Clinical Trials

Learn more about Alnylam-sponsored clinical trials your patients may be eligible for.

Learn More ›

Our Products

Learn more about our FDA-approved therapies.

Learn More ›

Alnylam Act®

Through Alnylam Act®, healthcare professionals can request genetic testing and counseling for hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 for individuals meeting certain criteria.

The Science Of RNAi

RNAi has helped create a new approach to developing medicine for genetic diseases.

Learn More ›